Table_1_Regional decreases of cortical thickness in major depressive disorder and their correlation with illness duration: a case-control study.DOCX by Fukun Wang (14131377)

The impact of the COVID-19 pandemic on the decrease in the use of intensive care units in the postoperative period of anatomic lung resections. A retrospective analysis by ISMAEL RODRIGO DIAS (12990222)

Data_Sheet_1_Higher Circulating Vitamin D Levels Are Associated With Decreased Migraine Risk: A Mendelian Randomization Study.pdf by Peng-Peng Niu (9985898)

“…Using pooled migraine summary data with no sample overlap, MR analysis showed per standard deviation increase in circulating vitamin D levels was significantly associated with a decreased migraine risk (OR = 0.916, 95% CI = 0.859–0.977, p = 0.008). …”

Image_2_Decreased Opioid Consumption in Bone Marrow Harvest Patients Using Quadratus Lumborum Blocks in a Standardized Protocol.PDF by Nicole C. McCoy (12459036)

Image_1_Decreased Opioid Consumption in Bone Marrow Harvest Patients Using Quadratus Lumborum Blocks in a Standardized Protocol.PDF by Nicole C. McCoy (12459036)

Image_3_Decreased Opioid Consumption in Bone Marrow Harvest Patients Using Quadratus Lumborum Blocks in a Standardized Protocol.PDF by Nicole C. McCoy (12459036)

Table_1_Risk of psychological distress by decrease in economic activity, gender, and age due to COVID-19: A multinational study.DOCX by Minji Kim (1722313)

Table_1_Co-occurrence of non-alcoholic steatohepatitis exacerbates psoriasis associated with decreased adiponectin expression in a murine model.docx by Daiki Takezaki (16825605)

Evaluation of glucose consumption and lactate production in culture medium of HL-1 cells exposed to LG, NG, HG and IHG during 12 and 72h. by Patrick Mordel (17020879)

First-in-Class Hydrazide-Based HDAC6 Selective Inhibitor with Potent Oral Anti-Inflammatory Activity by Attenuating NLRP3 Inflammasome Activation by Kairui Yue (11874403)

“…Representative inhibitor <b>35m</b> exhibits potent HDAC6 inhibitory activity with an IC₅₀ value of 0.019 μM. To our surprise, <b>35m</b> establishes significant improvement in the pharmacokinetic property with much higher AUC_0‑inf (10292 ng·h/mL) and oral bioavailability (93.4%) than hydroximic acid-based HDAC6 inhibitors Tubastatin A and ACY-1215. …”

First-in-Class Hydrazide-Based HDAC6 Selective Inhibitor with Potent Oral Anti-Inflammatory Activity by Attenuating NLRP3 Inflammasome Activation by Kairui Yue (11874403)

“…Representative inhibitor <b>35m</b> exhibits potent HDAC6 inhibitory activity with an IC₅₀ value of 0.019 μM. To our surprise, <b>35m</b> establishes significant improvement in the pharmacokinetic property with much higher AUC_0‑inf (10292 ng·h/mL) and oral bioavailability (93.4%) than hydroximic acid-based HDAC6 inhibitors Tubastatin A and ACY-1215. …”

DataSheet1_LP340, a novel histone deacetylase inhibitor, decreases liver injury and fibrosis in mice: role of oxidative stress and microRNA-23a.docx by Devadoss J. Samuvel (18572854)

Source data for Fig 1. by Rahsan Erdem (11726357)

Source data for Fig 2. by Rahsan Erdem (11726357)

Source data for Fig 3. by Rahsan Erdem (11726357)

Demographics and baseline characteristics of the safety population. by Rahsan Erdem (11726357)

Grading of stool consistency and diarrhea severity. by Rahsan Erdem (11726357)

Secondary efficacy endpoints for the modified intent-to-treat population. by Rahsan Erdem (11726357)

Source data for S1 and S2 Figs. by Rahsan Erdem (11726357)

Consolidated Standards for Reporting of Trials flow diagram. by Rahsan Erdem (11726357)